Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort
© 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology..
OBJECTIVE: The goals of this study were to assess the associations of severe nonadherence to hydroxychloroquine (HCQ), objectively assessed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality rates over five years of follow-up.
METHODS: The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort is an international multicenter initiative (33 centers throughout 11 countries). The serum of patients prescribed HCQ for at least three months at enrollment were analyzed. Severe nonadherence was defined by a serum HCQ level <106 ng/mL or <53 ng/mL for HCQ doses of 400 or 200 mg/day, respectively. Associations with the risk of a flare (defined as a Systemic Lupus Erythematosus Disease Activity Index 2000 increase ≥4 points, initiation of prednisone or immunosuppressive drugs, or new renal involvement) were studied with logistic regression, and associations with damage (first SLICC/American College of Rheumatology Damage Index [SDI] increase ≥1 point) and mortality with separate Cox proportional hazard models.
RESULTS: Of the 1,849 cohort participants, 660 patients (88% women) were included. Median (interquartile range) serum HCQ was 388 ng/mL (244-566); 48 patients (7.3%) had severe HCQ nonadherence. No covariates were clearly associated with severe nonadherence, which was, however, independently associated with both flare (odds ratio 3.38; 95% confidence interval [CI] 1.80-6.42) and an increase in the SDI within each of the first three years (hazard ratio [HR] 1.92 at three years; 95% CI 1.05-3.50). Eleven patients died within five years, including 3 with severe nonadherence (crude HR 5.41; 95% CI 1.43-20.39).
CONCLUSION: Severe nonadherence was independently associated with the risks of an SLE flare in the following year, early damage, and five-year mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Arthritis & rheumatology (Hoboken, N.J.) - 75(2023), 12 vom: 21. Dez., Seite 2195-2206 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 30.11.2023 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/art.42645 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359599346 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359599346 | ||
| 003 | DE-627 | ||
| 005 | 20240323000049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/art.42645 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM359599346 | ||
| 035 | |a (NLM)37459273 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nguyen, Yann |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2023 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. | ||
| 520 | |a OBJECTIVE: The goals of this study were to assess the associations of severe nonadherence to hydroxychloroquine (HCQ), objectively assessed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality rates over five years of follow-up | ||
| 520 | |a METHODS: The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort is an international multicenter initiative (33 centers throughout 11 countries). The serum of patients prescribed HCQ for at least three months at enrollment were analyzed. Severe nonadherence was defined by a serum HCQ level <106 ng/mL or <53 ng/mL for HCQ doses of 400 or 200 mg/day, respectively. Associations with the risk of a flare (defined as a Systemic Lupus Erythematosus Disease Activity Index 2000 increase ≥4 points, initiation of prednisone or immunosuppressive drugs, or new renal involvement) were studied with logistic regression, and associations with damage (first SLICC/American College of Rheumatology Damage Index [SDI] increase ≥1 point) and mortality with separate Cox proportional hazard models | ||
| 520 | |a RESULTS: Of the 1,849 cohort participants, 660 patients (88% women) were included. Median (interquartile range) serum HCQ was 388 ng/mL (244-566); 48 patients (7.3%) had severe HCQ nonadherence. No covariates were clearly associated with severe nonadherence, which was, however, independently associated with both flare (odds ratio 3.38; 95% confidence interval [CI] 1.80-6.42) and an increase in the SDI within each of the first three years (hazard ratio [HR] 1.92 at three years; 95% CI 1.05-3.50). Eleven patients died within five years, including 3 with severe nonadherence (crude HR 5.41; 95% CI 1.43-20.39) | ||
| 520 | |a CONCLUSION: Severe nonadherence was independently associated with the risks of an SLE flare in the following year, early damage, and five-year mortality | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Blanchet, Benoît |e verfasserin |4 aut | |
| 700 | 1 | |a Urowitz, Murray B |e verfasserin |4 aut | |
| 700 | 1 | |a Hanly, John G |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Bae, Sang-Cheol |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Diaz, Juanita |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez-Guerrero, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Ann E |e verfasserin |4 aut | |
| 700 | 1 | |a Bernatsky, Sasha |e verfasserin |4 aut | |
| 700 | 1 | |a Wallace, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Isenberg, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Anisur |e verfasserin |4 aut | |
| 700 | 1 | |a Merrill, Joan T |e verfasserin |4 aut | |
| 700 | 1 | |a Fortin, Paul R |e verfasserin |4 aut | |
| 700 | 1 | |a Gladman, Dafna D |e verfasserin |4 aut | |
| 700 | 1 | |a Bruce, Ian N |e verfasserin |4 aut | |
| 700 | 1 | |a Petri, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Ginzler, Ellen M |e verfasserin |4 aut | |
| 700 | 1 | |a Dooley, Mary Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsey-Goldman, Rosalind |e verfasserin |4 aut | |
| 700 | 1 | |a Manzi, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Jönsen, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Alarcón, Graciela S |e verfasserin |4 aut | |
| 700 | 1 | |a Van Vollenhoven, Ronald F |e verfasserin |4 aut | |
| 700 | 1 | |a Aranow, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Le Guern, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Mackay, Meggan |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Irastorza, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, S Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Inanc, Murat |e verfasserin |4 aut | |
| 700 | 1 | |a Kalunian, Kenneth C |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobsen, Søren |e verfasserin |4 aut | |
| 700 | 1 | |a Peschken, Christine A |e verfasserin |4 aut | |
| 700 | 1 | |a Kamen, Diane L |e verfasserin |4 aut | |
| 700 | 1 | |a Askanase, Anca |e verfasserin |4 aut | |
| 700 | 1 | |a Buyon, Jill |e verfasserin |4 aut | |
| 700 | 1 | |a Costedoat-Chalumeau, Nathalie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis & rheumatology (Hoboken, N.J.) |d 2014 |g 75(2023), 12 vom: 21. Dez., Seite 2195-2206 |w (DE-627)NLM234543671 |x 2326-5205 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2023 |g number:12 |g day:21 |g month:12 |g pages:2195-2206 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/art.42645 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2023 |e 12 |b 21 |c 12 |h 2195-2206 | ||